UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 654

Sortiert nach

Astragaloside IV alleviates ischemia reperfusion-induced apoptosis by inhibiting the activation of key factors in death receptor pathway and mitochondrial pathway

Journal of ethnopharmacology, 2020-02, Vol.248, p.112319-112319, Article 112319

2020

Link zum Volltext

Verfügbarkeit prüfen

Renal protective effects of astragaloside IV, in diabetes mellitus kidney damage animal models: A systematic review, meta-analysis

Pharmacological research, 2020-10, Vol.160, p.105192-105192, Article 105192

2020

Link zum Volltext

Verfügbarkeit prüfen

Astragaloside IV enhances taxol chemosensitivity of breast cancer via caveolin‐1‐targeting oxidant damage

Journal of cellular physiology, 2019-04, Vol.234 (4), p.4277-4290

2019

Link zum Volltext

Verfügbarkeit prüfen

Astragaloside IV improves renal function and fibrosis via inhibition of miR-21-induced podocyte dedifferentiation and mesangial cell activation in diabetic mice

Drug design, development and therapy, 2018-01, Vol.12, p.2431-2442

2018

Link zum Volltext

Verfügbarkeit prüfen

Astragaloside IV protects cardiomyocytes from anoxia/reoxygenation injury by upregulating the expression of Hes1 protein

Canadian journal of physiology and pharmacology, 2016-05, Vol.94 (5), p.542

2016

Link zum Volltext

Verfügbarkeit prüfen

Astragaloside IV promotes cerebral tissue restoration through activating AMPK- mediated microglia polarization in ischemic stroke rats

Journal of ethnopharmacology, 2024-11, Vol.334, p.118532, Article 118532

2024

Link zum Volltext

Verfügbarkeit prüfen

Astragaloside IV prevents Aβ1-42 oligomers-induced memory impairment and hippocampal cell apoptosis by promoting PPARγ/BDNF signaling pathway

Brain research, 2020-11, Vol.1747, p.147041, Article 147041

2020

Link zum Volltext

Verfügbarkeit prüfen

Astragaloside IV protects blood-brain barrier integrity from LPS-induced disruption via activating Nrf2 antioxidant signaling pathway in mice

Toxicology and applied pharmacology, 2018-02, Vol.340, p.58-66

2018

Link zum Volltext

Verfügbarkeit prüfen

Astragaloside IV acts through multi-scale mechanisms to effectively reduce diabetic nephropathy

Pharmacological research, 2020-07, Vol.157, p.104831-104831, Article 104831

2020

Link zum Volltext

Verfügbarkeit prüfen

Astragaloside IV derived from Astragalus membranaceus: A research review on the pharmacological effects

Advances in pharmacology (1990), 2020, Vol.87, p.89-112

2020

Link zum Volltext

Verfügbarkeit prüfen

Proteomic and lipidomic analysis of the mechanism underlying astragaloside IV in mitigating ferroptosis through hypoxia-inducible factor 1α/heme oxygenase 1 pathway in renal tubular epithelial cells in diabetic kidney disease

Journal of ethnopharmacology, 2024-11, Vol.334, p.118517, Article 118517

2024

Link zum Volltext

Verfügbarkeit prüfen

Astragaloside IV against Alzheimer's disease via microglia-mediated neuroinflammation using network pharmacology and experimental validation

European journal of pharmacology, 2023-10, Vol.957, p.175992-175992, Article 175992

2023

Link zum Volltext

Verfügbarkeit prüfen

Astragaloside IV Induces Apoptosis, G1-Phase Arrest and Inhibits Anti-apoptotic Signaling in Hepatocellular Carcinoma

In vivo (Athens), 2020-03, Vol.34 (2), p.631-638

2020

Link zum Volltext

Verfügbarkeit prüfen

Pharmacodynamic study: Astragaloside IV/chitosan/polylactic acid composite electrospinning scaffold for wound healing in diabetic rats

Journal of drug delivery science and technology, 2024-06, Vol.96, p.105632, Article 105632

2024

Link zum Volltext

Verfügbarkeit prüfen

Preventive effects of astragaloside IV and its active sapogenin cycloastragenol on cardiac fibrosis of mice by inhibiting the NLRP3 inflammasome

European journal of pharmacology, 2018-08, Vol.833, p.545-554

2018

Link zum Volltext

Verfügbarkeit prüfen

A network pharmacology approach to investigate the blood enriching mechanism of Danggui buxue Decoction

Journal of ethnopharmacology, 2019-05, Vol.235, p.227-242

2019

Link zum Volltext

Verfügbarkeit prüfen

Astragaloside IV regulates TL1A and NF-κB signal pathway to affect inflammation in necrotizing enterocolitis

Tissue & cell, 2023-08, Vol.83, p.102128-102128, Article 102128

2023

Link zum Volltext

Verfügbarkeit prüfen

Astragaloside IV attenuates myocardial ischemia/reperfusion injury in rats via inhibition of calcium-sensing receptor-mediated apoptotic signaling pathways

Acta pharmacologica Sinica, 2019-05, Vol.40 (5), p.599-607

2019

Link zum Volltext

Verfügbarkeit prüfen

SENP2-NDR2-p21 axis modulates lung cancer cell growth

European journal of pharmacology, 2024-09, Vol.978, p.176761, Article 176761

2024

Link zum Volltext

Verfügbarkeit prüfen

Astragaloside-IV alleviates high glucose-induced ferroptosis in retinal pigment epithelial cells by disrupting the expression of miR-138-5p/Sirt1/Nrf2

Bioengineered, 2022-04, Vol.13 (4), p.8238-8253

2022

Link zum Volltext

Verfügbarkeit prüfen

Phenylsulfate-induced oxidative stress and mitochondrial dysfunction in podocytes are ameliorated by Astragaloside IV activation of the SIRT1/PGC1α /Nrf1 signaling pathway

Biomedicine & pharmacotherapy, 2024-08, Vol.177, p.117008, Article 117008

2024

Link zum Volltext

Verfügbarkeit prüfen

Nose to brain delivery of Astragaloside IV by β-Asarone modified chitosan nanoparticles for multiple sclerosis therapy

International journal of pharmaceutics, 2023-09, Vol.644, p.123351-123351, Article 123351

2023

Link zum Volltext

Verfügbarkeit prüfen

ZnO-S.cerevisiae: An effective growth promoter of Astragalus memeranaceus and nano-antifungal agent against Fusarium oxysporum

Chemical engineering journal (Lausanne, Switzerland : 1996), 2024-04, Vol.486, p.149958, Article 149958

2024

Link zum Volltext

Verfügbarkeit prüfen

Astragaloside IV inhibits cardiac fibrosis via miR-135a-TRPM7-TGF-β/Smads pathway

Journal of ethnopharmacology, 2020-03, Vol.249, p.112404-112404, Article 112404

2020

Link zum Volltext

Verfügbarkeit prüfen

Association of astragaloside IV-inhibited autophagy and mineralization in vascular smooth muscle cells with lncRNA H19 and DUSP5-mediated ERK signaling

Toxicology and applied pharmacology, 2019-02, Vol.364, p.45-54

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 654

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(595)
Mit Volltextzugriff
(617)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Astragaloside IV alleviates ischemia reperfusion-induced apoptosis by inhibiting the activation of key factors in death receptor pathway and mitochondrial pathway

Renal protective effects of astragaloside IV, in diabetes mellitus kidney damage animal models: A systematic review, meta-analysis

Astragaloside IV enhances taxol chemosensitivity of breast cancer via caveolin‐1‐targeting oxidant damage

Astragaloside IV improves renal function and fibrosis via inhibition of miR-21-induced podocyte dedifferentiation and mesangial cell activation in diabetic mice

Astragaloside IV protects cardiomyocytes from anoxia/reoxygenation injury by upregulating the expression of Hes1 protein

Astragaloside IV promotes cerebral tissue restoration through activating AMPK- mediated microglia polarization in ischemic stroke rats

Astragaloside IV prevents Aβ1-42 oligomers-induced memory impairment and hippocampal cell apoptosis by promoting PPARγ/BDNF signaling pathway

Astragaloside IV protects blood-brain barrier integrity from LPS-induced disruption via activating Nrf2 antioxidant signaling pathway in mice

Astragaloside IV acts through multi-scale mechanisms to effectively reduce diabetic nephropathy

Astragaloside IV derived from Astragalus membranaceus: A research review on the pharmacological effects

Proteomic and lipidomic analysis of the mechanism underlying astragaloside IV in mitigating ferroptosis through hypoxia-inducible factor 1α/heme oxygenase 1 pathway in renal tubular epithelial cells in diabetic kidney disease

Astragaloside IV against Alzheimer's disease via microglia-mediated neuroinflammation using network pharmacology and experimental validation

Astragaloside IV Induces Apoptosis, G1-Phase Arrest and Inhibits Anti-apoptotic Signaling in Hepatocellular Carcinoma

Pharmacodynamic study: Astragaloside IV/chitosan/polylactic acid composite electrospinning scaffold for wound healing in diabetic rats

Preventive effects of astragaloside IV and its active sapogenin cycloastragenol on cardiac fibrosis of mice by inhibiting the NLRP3 inflammasome

A network pharmacology approach to investigate the blood enriching mechanism of Danggui buxue Decoction

Astragaloside IV regulates TL1A and NF-κB signal pathway to affect inflammation in necrotizing enterocolitis

Astragaloside IV attenuates myocardial ischemia/reperfusion injury in rats via inhibition of calcium-sensing receptor-mediated apoptotic signaling pathways

SENP2-NDR2-p21 axis modulates lung cancer cell growth

Astragaloside-IV alleviates high glucose-induced ferroptosis in retinal pigment epithelial cells by disrupting the expression of miR-138-5p/Sirt1/Nrf2

Phenylsulfate-induced oxidative stress and mitochondrial dysfunction in podocytes are ameliorated by Astragaloside IV activation of the SIRT1/PGC1α /Nrf1 signaling pathway

Nose to brain delivery of Astragaloside IV by β-Asarone modified chitosan nanoparticles for multiple sclerosis therapy

ZnO-S.cerevisiae: An effective growth promoter of Astragalus memeranaceus and nano-antifungal agent against Fusarium oxysporum

Astragaloside IV inhibits cardiac fibrosis via miR-135a-TRPM7-TGF-β/Smads pathway

Association of astragaloside IV-inhibited autophagy and mineralization in vascular smooth muscle cells with lncRNA H19 and DUSP5-mediated ERK signaling

Suchergebnisse filtern